Last reviewed · How we verify
IMSA101
At a glance
| Generic name | IMSA101 |
|---|---|
| Sponsor | ImmuneSensor Therapeutics Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer (PHASE2)
- Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC (PHASE2)
- Safety and Efficacy Study of IMSA101 in Refractory Malignancies (PHASE1, PHASE2)
- Study of PULSAR-ICI +/- IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies (PHASE2)
- A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |